Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827489 | 1.00 | MLYCD (0.52) | MLYCDGPBAR1TRPV4PTPN1BCHE | |
| SCHEMBL30521565 | 0.90 | MLYCD (0.51) | MLYCDGPBAR1PTPN1BCHEACHE | |
| SCHEMBL25804625 | 0.90 | MLYCD (0.51) | MLYCDGPBAR1PTPN1BCHEACHE | |
| SCHEMBL15648560 | 0.86 | MLYCD (0.48) | MLYCDGPBAR1BCHEACHERORC | |
| SCHEMBL14299992 | 0.84 | MLYCD (0.49) | MLYCDTRPV4MRGPRX4CSF1R | |
| SCHEMBL17823828 | 0.81 | MLYCD (0.50) | MLYCDBCHEACHERORCL3MBTL1 | |
| SCHEMBL2713528 | 0.80 | L3MBTL1 (0.63) | MLYCDL3MBTL1SCN9A | |
| SCHEMBL15351311 | 0.80 | SCN9A (0.41) | MLYCDGPBAR1MRGPRX4SCN9ACSF1R | |
| SCHEMBL2571770 | 0.80 | MLYCD (0.49) | MLYCDBCHEACHERORCL3MBTL1 | |
| SCHEMBL2269574 | 0.78 | MLYCD (0.52) | MLYCDBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN BIOTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117881661-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4347036-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| WO-2022253255-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253255-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1423381-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060194857-A1 | Novel heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647546-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194857-A1 | Novel heteroaryl derivative | NR0B1, UGT1A10, NR0B2 | MLYCD 3307/4885GPBAR1 153/4885TRPV4 2166/4885 |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | MLYCD 2810/4885GPBAR1 407/4885TRPV4 497/4885 |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | MLYCD 2810/4885GPBAR1 407/4885TRPV4 497/4885 |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | MLYCD 213/4885GPBAR1 248/4885TRPV4 4510/4885 |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | HRH2, HRH1, HRH4 | MLYCD 3102/4885GPBAR1 93/4885TRPV4 252/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | MLYCD 3188/4885GPBAR1 272/4885TRPV4 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.